With respect to rheumatoid arthritis and psoriasis, phase Ib/IIa clinical trials for a C5a inhibitor have already been completed 47, and a similar therapeutic strategy using complement factor C5a as a target may be promising in the prevention of acute cardiovascular events. This evidence concerns the gene C5 and psoriasis.